<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The present study was undertaken to evaluate the effects of <z:hpo ids='HP_0011010'>chronic</z:hpo> treatment with c-AUCB {cis-4-[4-(3-<z:chebi fb="0" ids="40519">adamantan</z:chebi>-1-ylureido)<z:chebi fb="0" ids="52552">cyclohexyl</z:chebi>-oxy]<z:chebi fb="0" ids="30746">benzoic acid</z:chebi>}, a novel inhibitor of sEH (soluble <z:chebi fb="0" ids="32955">epoxide</z:chebi> hydrolase), which is responsible for the conversion of biologically active EETs (epoxyeicosatrienoic acids) into biologically inactive DHETEs (dihydroxyeicosatrienoic acids), on BP (blood pressure) and myocardial <z:mpath ids='MPATH_124'>infarct</z:mpath> size in male heterozygous TGR (Ren-2 renin transgenic rats) with established <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">Myocardial ischaemia</z:e> was induced by coronary <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Systolic BP was measured in conscious animals by tail plethysmography </plain></SENT>
<SENT sid="4" pm="."><plain>c-AUCB was administrated in drinking water </plain></SENT>
<SENT sid="5" pm="."><plain>Renal and myocardial concentrations of EETs and DHETEs served as markers of internal production of epoxygenase metabolites </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> treatment with c-AUCB, which resulted in significant increases in the availability of biologically active epoxygenase metabolites in TGR (assessed as the ratio of EETs to DHETEs), was accompanied by a significant reduction in BP and a significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size in TGR as compared with untreated TGR </plain></SENT>
<SENT sid="7" pm="."><plain>The cardioprotective action of c-AUCB treatment was completely prevented by <z:hpo ids='HP_0011009'>acute</z:hpo> administration of a selective EETs <z:chebi fb="68" ids="48706">antagonist</z:chebi> [14,15-epoxyeicosa-5(Z)-enoic acid], supporting the notion that the improved cardiac ischaemic tolerance conferred by sEH inhibition is mediated by EETs actions at the cellular level </plain></SENT>
<SENT sid="8" pm="."><plain>These findings indicate that <z:hpo ids='HP_0011010'>chronic</z:hpo> inhibition of sEH exhibits <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> and cardioprotective actions in this <z:e sem="disease" ids="C1519606" disease_type="Experimental Model of Disease" abbrv="">transgenic model</z:e> of <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi>-dependent <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
</text></document>